---
title: "Novonesis: Global uncertainty catalysing increased biosolutions demand"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285345864.md"
description: "Ester Baiget, CEO of Novonesis discusses Q1 earnings, and explains why the company does not expect a significant impact from the Middle East conflict."
datetime: "2026-05-06T09:21:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285345864.md)
  - [en](https://longbridge.com/en/news/285345864.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285345864.md)
generator: "portal-rs"
---

# Novonesis: Global uncertainty catalysing increased biosolutions demand

Ester Baiget, CEO of Novonesis discusses Q1 earnings, and explains why the company does not expect a significant impact from the Middle East conflict.

### Related Stocks

- [NVNXF.US](https://longbridge.com/en/quote/NVNXF.US.md)
- [NVX.AU](https://longbridge.com/en/quote/NVX.AU.md)

## Related News & Research

- [Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio | RVVTF Stock News](https://longbridge.com/en/news/296357987.md)
- [Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses](https://longbridge.com/en/news/296405637.md)
- [Nexgel’s Celularity Deal: Execution, Integration, and Profitability Risks from $13.3 Million Biomaterials Acquisition](https://longbridge.com/en/news/296183101.md)
- [BioNxt completes IMPD, moves toward first human bioequivalence trial for sublingual cladribine film in MS](https://longbridge.com/en/news/296314929.md)
- [04:20 ETSphingoTec to Engage with Clinical and Industry Partners at Major 2026 Conferences](https://longbridge.com/en/news/296322953.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**